Regeneron stock: buy or sell?

REGN stock price: $295.87 3.40% At close on September 20th, 2019

Updated on:
September 20th, 2019


Regeneron broke up the simple moving average line of 50d today and closed at $295.87, boosted a 3.40%.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide.

Should I buy Regeneron stock?

Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best time to buy them. At, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

None of our preferred buy setups matches with Regeneron Pharmaceuticals stock situation right now, hence this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean REGN will slide in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is Regeneron stock a buy?

Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness. At, we gathered 15 ratings published for REGN stock in the last month.

Is REGN a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-8-7Robert W. BairdNeutralOutperform
2019-8-7Credit Suisse Groupn/aNeutral
2019-8-7BMO Capital Marketsn/aMarket Perform
2019-5-8UBS Groupn/aBuy
2019-5-8Morgan Stanleyn/aEqual Weight
2019-4-17Jefferies Financial Groupn/aHold
2019-2-7BMO Capital Marketsn/aMarket Perform
2019-2-6Cantor Fitzgeraldn/aHold
2019-2-26Piper Jaffray Companiesn/aOverweight

Regeneron stock analysis

Daily outlook

Regeneron shares broke up the simple moving average line of 50 days today and closed at $295.87, boosted a 3.40%.

Regeneron shares crossed up the SMA line of 50 days today and closed at $295.87, boosted a 3.40%.

REGN stock chart (daily)

Weekly outlook

Shares of Regeneron boosted a brilliant 5.06% this week.

Since early April, when REGN stock price broke down the 40-weeks moving avarage line, it slid $-113.07 per share (-27.65%). Stocks below the 40-weeks moving average line are usually not recommended for average traders.

REGN stock chart (weekly)

Regeneron stock price history

Regeneron stock went public on April 2nd, 1991 with a price of $22.001. Since then, REGN stock surged a 1,244.90%, with a yearly average of 44.50%. If you had invested $1,000 in Regeneron stock in 1991, it would worth $12,449.00 today.

1: Adjusted price after possible price splits or reverse-splits.

Regeneron stock historical price chart

REGN stock reached 52-week highs on March at $442.00, and all-time highs 2015-08-04 with a price of 605.93.

Regeneron stock price target is $397.00

How much a stock will be priced tomorrow or next week is quite unpredictable However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. You should not follow the analysts' REGN stock price predictions in the hope that they will be met as they may be wrong and not met. We detected 12 price forecasts for Regeneron Pharmaceuticals stock released in the last 30 days:
REGN stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-8-7Robert W. BairdUpgradesn/a$410.00-
2019-8-7Credit Suisse GroupReiterates$333.00$325.00-2.4%
2019-8-7BMO Capital MarketsLowers Targetn/a$344.00-
2019-5-8UBS GroupLowers Targetn/a$440.00-
2019-5-8Morgan StanleyLowers Target$420.00$389.00-7.4%
2019-4-17Jefferies Financial GroupLowers Target$376.00$343.00-8.8%
2019-2-7OppenheimerRaises Target$440.00$480.009.1%
2019-2-7BMO Capital MarketsRaises Targetn/a$412.00-
2019-2-6Cantor FitzgeraldReiteratesn/a$441.00-
2019-2-26Piper Jaffray CompaniesRaises Targetn/a$487.00-
(in average)$393.00$397.001.0%
The price prediction for Regeneron Pharmaceuticals stock is $397.00, moving in a range between $487.00 and $325.00. In average, analysts' outlook on REGN price forecast is stable from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

On February, Regeneron Pharmaceuticals presented its financial report, posting a more than good growth for the Earnings per Share (EPS). Analyst expected $5.10 per share, but Regeneron Pharmaceuticals posted $5.92.
REGN earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

Compared to 2017, last anual revenues report draw an exceptional gain of 14.28% to $6,710.80 M USD. Aligned with this, its profit margin (compared to sales) rocketed to 36.42%, that is $2,444.40 million.

REGN annual Sales and Income evolution
2013$2,100 M-$424 M20.2%-
2014$2,820 M34.26%$348 M12.3%-17.98%
2015$4,104 M45.55%$636 M15.5%82.74%
2016$4,860 M18.44%$896 M18.4%40.79%
2017$5,872 M20.82%$1,199 M20.4%33.83%
2018$6,711 M14.28%$2,444 M36.4%103.95%

Quarterly financial results

Regeneron posted $1,927.80 million in sales for 2018-Q4, a 15.89% up compared to previous quarter. Reported quarter income marked $820.35 million with a profit margin of 42.55%. Profit margin escalated a 6.81% compared to previous quarter when profit margin was 35.75%. When comparing turnover to same quarter last year, Regeneron Pharmaceuticals sales marked an outstanding increase and skyrocketed a 21.82%. Looking back to recent quarterly results, Regeneron Pharmaceuticals posted 3 negative quarters in a row.
REGN quarterly Sales and Income evolution
2017-Q1$1,320 M-$249 M18.9%-
2017-Q2$1,470 M11.36%$388 M26.4%55.76%
2017-Q3$1,501 M2.09%$388 M25.9%0.15%
2017-Q4$1,582 M5.45%$174 M11.0%-55.32%
2018-Q1$1,511 M-4.48%$478 M31.6%175.46%
2018-Q2$1,608 M6.39%$551 M34.3%15.36%
2018-Q3$1,664 M3.45%$595 M35.7%7.84%
2018-Q4$1,928 M15.89%$820 M42.6%37.95%

Regeneron ownership

When you are planning to invest in a stock, it's always worth to check its ownership structure.

Regeneron Pharmaceuticals shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 24.61% of all shares.

In case of Regeneron Pharmaceuticals stock, 72.68% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for REGN stock account 0.00%, no big difference from last month.

For a better context understanding, the next table shows ownership data compared to other related companies:

Market cap$31.9 B$9.4 B$118.1 B$43.5 B$343.5 B
Total shares108.0 M111.2 M599.7 M184.5 M2,640.0 M
Float shares81.2 M110.2 M598.3 M184.0 M2,630.0 M
  - Institutional holdings (%)72.7%88.2%81.9%93.4%69.2%
  - Insider holdings (%)24.6%10.8%0.2%0.5%0.1%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

Regeneron summary

Friday, September 20th, 2019
Day range$288.31 - $297.64
Previous close$286.15
Session gain3.40%
Average true range$7.82
50d mov avg$295.48
100d mov avg$303.61
200d mov avg$349.79
Daily patternlt03a
Weekly pattern lb06a

Regeneron performance

To better understand Regeneron Pharmaceuticals performance you must becnhmark its gains with other related stocks in same sector or industry. For Regeneron, the comparison is made against Alnylam Pharmaceuticals, Amgen, Biogen, , Novartis and .
REGNRegeneron Pharmac...-7.62%-24.48%-24.19%
ALNYAlnylam Pharmaceu...13.76%0.09%-10.54%

Regeneron competitors

One check before investing in any stock is to review a list of its competitors, in this case for Regeneron Pharmaceuticals. We chose 6 companies as Regeneron Pharmaceuticals competitors as they are in the same industry or have similar market objectives.

Latest Regeneron stock news